Core Points - SenesTech, Inc. announced the closing of the exercise of outstanding warrants to purchase 1,458,872 shares of common stock at an exercise price of $2.90 per share, generating approximately $4.4 million in gross proceeds [1][4] - The company issued new unregistered short-term warrants for the same number of shares at an exercise price of $4.15 per share, with a purchase price of $0.125 per warrant, potentially raising an additional $6.0 million if fully exercised [3][4] - The net proceeds from the transaction are intended for working capital and general corporate purposes [4] Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, having developed products like ContraPest®, the only U.S. EPA-registered contraceptive for rats, and Evolve™ products for rodents [8]

About FemaSeed FemaSeed is a next-generation artificial insemination solution that enhances fertilization by precisely delivering sperm to the fallopian tube, the natural site of conception. Offering a safe, accessible, and cost-effective first- line treatment, FemaSeed provides a more effective alternative to intrauterine insemination (IUI). In the pivotal clinical trial (NCT0468847), it achieved over double the pregnancy rates of IUI in cases of low male sperm count. FemaSeed is an affordable, less invasi ...

Scientists in China have presented the most complete attempt yet at making healthy, fertile mice from two sperm cells. Bipaternal human children, though, are still far away https://t.co/6pVZZVcFQy ...

People who have kids do need to have 3 kids to make up for those who have 0 or 1 kid or population will collapseMario Nawfal (@MarioNawfal):HUMANS NEED 2.7 KIDS PER WOMAN TO SURVIVE... WE'RE NOT EVEN CLOSEScientists now say 2.1 kids per woman won’t cut it - 2.7 is the real number needed to avoid long-term extinction.Right now, the U.S. is at 1.66, and most rich countries are even lower, including Italy at 1.29 https://t.co/FF4Y9pVVRd ...

RT Wall Street Mav (@WallStreetMav)Japan population is collapsing. The country has more deaths than births with its fertility rate below replacement levels.They need to start making more babies in Japan.Which policies are need to turn this around? https://t.co/VKhs6GSsXC ...

Pallet and Container Orders Expected for Resupply and ExpansionSURPRISE, Ariz., June 26, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), a leader in fertility control for managing animal pest populations, today announced compelling results from two major urban deployments — one in Hong Kong and one in San Francisco — showing how pairing Evolve™ Rat Birth Control with traditional poison bait stations delivers faster, more sustainable rodent control where it's needed most.Gl ...

RT Polymarket (@Polymarket)U.S. fertility rates are projected to continue their decline.Is the U.S. headed toward population collapse? ...

Strategic Partnership Expands National Reach and Accelerates Retail & Dealer Access Across Rural America SURPRISE, Ariz., June 11, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the leader in fertility control for managing animal pest populations, today announced a distribution agreement with Bradley Caldwell, Inc. (BCI), a premier wholesale distributor serving over 8,000 farm, ranch, hardware, and pet supply dealers across the United States. This new partnership signific ...

America's fertility rates are hovering around historic lows, with approximately 1.6% births per woman over her lifetime. This is below the level needed to sustain the population, which is 2.1% births per woman. We're actually projecting that about 1 in 4 young adults today will never have kids.There are plenty of us out there who are kind of concerned about the falling birth rate, both for kind of its impact on people's ordinary lives, as well as for the ways in which it will affect our economy and our gove ...

Financial Data and Key Metrics Changes - Consolidated revenues were $1,002 million, up 6% year over year or up 7% organically [7] - Non-GAAP earnings were $0.96, up 14% year over year [24] - Consolidated gross margin was 68%, up from 67.3% [21] - Operating expenses increased 6% but declined as a percentage of revenue to 43.1% [22] Business Line Data and Key Metrics Changes - CooperVision reported revenues of $670 million, up 5% or up 7% organically [7] - CooperSurgical posted revenues of $333 million, up 8% or up 7% organically [14] - Daily silicone hydrogel lenses grew 10%, with Myopia management portfolio growing 19% [8][11] - Fertility revenues were $127 million, up 3% and up 2% organically, but lower than expected due to market softness [15] Market Data and Key Metrics Changes - The Americas grew 8%, EMEA grew 6%, and Asia Pac grew 5% for CooperVision [8] - The contact lens industry grew 4% in calendar Q1, leading to a reduction in growth expectations to 4% to 6% for the year [18][19] - Fertility market growth expectations were reduced to low single digits due to market softness, particularly in Asia Pac [19][41] Company Strategy and Development Direction - The company is focusing on operational improvements and product launches to drive growth [6] - There is a strong emphasis on increasing availability of MyDay and MiSight products in new markets [9][14] - The company is adjusting its revenue guidance to reflect solid Q2 performance and updated market assumptions [24][25] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a more complex global operating environment but emphasized strong execution and market share gains [6][20] - There is optimism about long-term growth fundamentals in fertility despite current market softness [16][41] - Management expects organic growth in Q4 to be stronger than Q3, supported by product rollouts and improved fitting activity [25][52] Other Important Information - The company repurchased approximately 537,000 shares for roughly $40.6 million, leaving $215.8 million available under the repurchase plan [24] - Tariffs are expected to have a negative impact of roughly $4 million on the cost of goods this year [26] - Currency fluctuations are anticipated to have a 0.5% headwind to revenues and a 1% headwind to earnings [26] Q&A Session Summary Question: Contact lens end market performance - Management noted that channel inventory pressures are affecting growth rates, but fitting activity remains strong [30][31] Question: Lower market growth assumption for Vision Care - The reduction in guidance is attributed to general market softness rather than specific pricing or volume issues [34][36] Question: Fertility market softness in Asia - Management indicated that the decline in fertility cycles in Asia is partly due to cultural factors and economic pressures [41][42] Question: Changes in consumer behavior regarding contact lens purchases - Management confirmed that consumers are buying shorter supply durations, impacting revenue despite strong fitting activity [46][47] Question: Guidance for Q3 and Q4 - Management expects Q3 results to be below the lower end of guidance, with Q4 anticipated to be at or above the top end [52] Question: Inventory expectations for the rest of the year - Management anticipates continued pressure on inventory levels throughout the year, affecting overall market growth [55][56] Question: Margin expectations moving forward - Management expects continued improvement in margins due to operational efficiencies and prior investment returns [70]